Serotonin Syndrome in the Emergency Department

Hernández, Michelle; Walsh, Michael; Stead, Trilok; Quinones, Anines; Ganti, Latha

doi:10.7759/cureus.6307

Cited by 4 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is speculated that drugs that modify 5-HT activity may have an inhibitory effect on LID. However, they require careful administration because an overdose of serotonin agonists leads to 5-HT syndrome, the symptomatology of which is similar (tremor and rigidity) to PD [ 120 ]. The 5-HT1A partial agonist buspirone inhibits LID in rats by influencing the 5-HT1A receptors, although it does not alter STN electrical activity [ 121 ].…”

Section: Resultsmentioning

confidence: 99%

Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review

Hutny

Hofman

Klimkowicz‐Mrowiec

et al. 2021

JCM

View full text Add to dashboard Cite

Levodopa remains the primary drug for controlling motor symptoms in Parkinson’s disease through the whole course, but over time, complications develop in the form of dyskinesias, which gradually become more frequent and severe. These abnormal, involuntary, hyperkinetic movements are mainly characteristic of the ON phase and are triggered by excess exogenous levodopa. They may also occur during the OFF phase, or in both phases. Over the past 10 years, the issue of levodopa-induced dyskinesia has been the subject of research into both the substrate of this pathology and potential remedial strategies. The purpose of the present study was to review the results of recent research on the background and treatment of dyskinesia. To this end, databases were reviewed using a search strategy that included both relevant keywords related to the topic and appropriate filters to limit results to English language literature published since 2010. Based on the selected papers, the current state of knowledge on the morphological, functional, genetic and clinical features of levodopa-induced dyskinesia, as well as pharmacological, genetic treatment and other therapies such as deep brain stimulation, are described.

show abstract

Section: Resultsmentioning

confidence: 99%

Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review

Hutny

Hofman

Klimkowicz‐Mrowiec

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…It was observed that modification of the serotonergic system exerts an inhibitory effect on LID. However, careful administration is required as an overdose of serotonergic agonists can lead to symptomatology (5-HT syndrome), which shows PD-like symptoms ( Hernandez et al, 2019 ). Buspirone, a partial 5-HT1A receptor agonist, was examined to be preventing the development of LID in rats without altering the STN electrical activity.…”

Section: Approaches For Management Of Levodopa-induced Dyskinesia: Pr...mentioning

confidence: 99%

Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence

et al. 2022

View full text Add to dashboard Cite

Parkinson’s disease (PD) is the second leading neurodegenerative disease that is characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been considered a mainstay for the management of PD; however, its prolonged treatment is often associated with abnormal involuntary movements and results in L-DOPA-induced dyskinesia (LID). Although LID is encountered after chronic administration of L-DOPA, the appearance of dyskinesia after weeks or months of the L-DOPA treatment has complicated our understanding of its pathogenesis. Pathophysiology of LID is mainly associated with alteration of direct and indirect pathways of the cortico-basal ganglia-thalamic loop, which regulates normal fine motor movements. Hypersensitivity of dopamine receptors has been involved in the development of LID; moreover, these symptoms are worsened by concurrent non-dopaminergic innervations including glutamatergic, serotonergic, and peptidergic neurotransmission. The present study is focused on discussing the recent updates in molecular mechanisms and therapeutic approaches for the effective management of LID in PD patients.

show abstract

“…It is speculated that drugs that modify 5-HT activity may have an inhibitory effect on LID. However, they require careful administration because overdose of serotonin agonists leads to 5-HT syndrome, symptomatology similar (tremor and rigidity) to PD [113]. The 5-HT1A partial agonist buspirone inhibits LID by influencing the 5-HT1A receptors, although it does not alter STN electrical activity [114].…”

Section: Serotonin In the Treatment Of Lidmentioning

confidence: 99%

Current Knowledge on the Background, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesia – Literature Review.

Hutny¹,

Hofman²,

Klimkowicz‐Mrowiec³

et al. 2021

Preprint

View full text Add to dashboard Cite

Levodopa remains the primary drug for controlling motor symptoms in Parkinson's disease through the whole course, but over time complications develop in the form of dyskinesias, which gradually become more frequent and severe. These abnormal, involuntary, hyperkinetic movements are mostly characteristic of the ON phase and reflect an excess of exogenous levodopa. They may also occur during OFF phase, or in both phases. Over the past 10 years, the issue of levodopa-induced dyskinesia has been the subject of research into both the substrate of this pathology and potential remedial strategies. The purpose of the present study was to review the results of recent research on the background and treatment of dyskinesia. To this end, databases were reviewed using a search strategy that included both relevant keywords related to the topic and appropriate filters to limit results to English-language literature published since 2010. Based on the selected papers, the current state of knowledge on morphological, functional, genetic, and clinical features of levodopa-induced dyskinesia, as well as pharmacological, genetic treatment and other therapies such as deep brain stimulation are described.

show abstract

Serotonin Syndrome in the Emergency Department

Cited by 4 publications

References 8 publications

Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review

Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review

Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence

Current Knowledge on the Background, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesia – Literature Review.

Contact Info

Product

Resources

About